Online inquiry

IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1650MR)

This product GTTS-WQ1650MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets GP6 gene. The antibody can be applied in Ischemic stroke research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001083899.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51206
UniProt ID Q9HCN6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1650MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14824MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SGN-75
GTTS-WQ13229MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-05082566
GTTS-WQ2319MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALXN6000
GTTS-WQ4737MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BOS161721
GTTS-WQ6263MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ15296MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Theraloc
GTTS-WQ3863MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BCD-089
GTTS-WQ6461MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CT-P23
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW